Generated by AI
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on developing oral combination medicines and psychedelic-based therapies for chronic conditions with limited treatment options. Incannex Healthcare Inc. is currently advancing programs in obstructive sleep apnea, generalized anxiety disorder, rheumatoid arthritis, and inflammatory disorders through its research and development of cannabinoid and psychedelic pharmaceutical products. Its pipeline includes fixed-dose and synthetic oral treatments designed to target underlying biological pathways and support clinical development across sleep medicine, mental health, and inflammation. Based in Sydney, Australia, Incannex Healthcare Inc. operates as a science-led developer of novel therapeutics aimed at addressing significant unmet medical needs in modern healthcare.
WebsiteRialto South Tower Level 23
Melbourne, VIC, 2153
Australia
The latest articles about IXHL.
First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI...
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Mar 25's posts. Generated by AI.
Summary of Mar 25's posts. Generated by AI.
Investors talking about IXHL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.